Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial

The study aimed to evaluate the efficacy of adding the tyrosine kinase inhibitor Quizartinib to intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS), regardless of FLT3 mutation status. While Quizartinib did not improve overall survival for the entire cohort, it significantly enhanced survival in FLT3-mutated patients, particularly those receiving a shorter duration of treatment. The findings suggest that Quizartinib may be beneficial for specific subgroups, highlighting the importance of genetic profiling in treatment strategies.